EMCDDA Home
  • EN
Search

Table INF-1. Prevalence of HIV infection among injecting drug users in the EU, Croatia, Turkey and Norway, 2011 or most recent year available (summary table by country)

Country or region% Infected (1)
YearNumber testedNational samplesSub-national samplesStudy design (2) Setting/comments (3, 4, 5) References
Belgium2011412:0.0-8.3DT ; SRDTC; serum27 ; 28 ; 99
Bulgaria20111140:2.8DTDTC; NSP; LTS; serum7d
Czech Republic201156960.3-0.9:DT ; SRSTI, OHC, HTC, DTC, LTS, NSP, GPS; PHL; serum, capillary blood28 ; 31 ; 32
Denmark 20061882.1:SP (UAT)ODD, 5 sites; IDUnk7
Germany 20115343.9 -5.6SPLTS; dried blood spots38
Estonia2010350:52.6SPNSP;Serum6
Ireland n.a.n.a.n.a.n.a.n.a.n.a.n.a.
Greece 201122383.7-4.40.0-8.1DT;SPDTC, LTS, PHL, OHC, PRI, STR, OTH; serum1 ; 2 ; 9 ; 18 ; 19 ;20
Spain2010724333.6:DTDTC; PRI; serum39 ; 40 ; 41 ; 42
France 201013377.2SRNSP; OLT;STR;22
Italy*20105840811.52.2 - 38.1DTDTC; serum IDUnk47 ; 48a ; 48b ; 49;50
Cyprus20113730.1-1.4:DT ; SRDTC, PRI; serum10 ; 11 ; 12
Latvia201172311.232.1DT ; SPNSP,STR; rapid HIV tests (capillary blood from finger), serum 17 ; 19
Lithuania2010720:0.0-21.4SRNSP14
Luxembourg20111711.8:SRDTC, OHC, PRI; serum8 ; 11 ;12
Hungary20118520.00.0SP ; DTDTC, NSP, dried blood spots24 ; 25
Malta20111150.0:DTDTC, HTC, PHL, STI, ANT, OHC; serum 5 ; 7; 8 ; 9 ; 10
Netherlands^^2010/201169:0.0 - 3.7DT DTC ; serum35 ; 36
Austria20116800.4-3.90.0-2.26DTNSP, LTS, ODD, DTC; serum2 ; 12 ; 13 ; 14
Poland20118842.9DTPHL, OTH; serum10 ; 11 ; 12 ; 20
Portugal***2010/201122074.9-16.5:DT ; SPDTC; serum, dried blood spots30 ; 31 ;32
Romania201121611.6SRDTC, NSP, LTS; serum, dried blood spots 4 ; 5 ; 6
Slovenia20113421.90.5SP (UAT) ; DTNSP, DTC; saliva, serum 5 ; 6 ; 8 ; 9 ;10 ;11
Slovakia20116150.40.0DT ; SPDTC, ODD, PRI, HTC; serum12 ; 13 ; 14 ; 15 ; 16 ; 17 ;18 ;19 ;20; 21
Finland 20096840.7SP (UAT)NSP; saliva8
Sweden2010181:4.4DTPRI; serum13 ;14
United Kingdom201149741.20.3-1.3SP (UAT)DTC, NSP, LTS, OTH; dried blood spots, saliva or other oral fluid 50 ; 51 ; 53 ; 54 ; 65;68;69;70;71;72;73
Croatian.a.n.a.n.a.n.a.n.a.n.a.n.a.
Turkey20117160.3:SP (UAT)DTC; serum0
Norway201151182.320.56SPNSP, DTC, LTS; serum16 ; 21 , 23 ; 25 ; 26
 

Notes:

This summary table gives a global overview of HIV prevalence in IDUs in the EU, 2011 or most recent year available. Data for more than one year are combined if they clearly improve generalisability (e.g. national data, out-of-treatment data). Prevalence in this table should not be compared with previous versions to follow changes over time, as inclusion of sources may vary according to data availability. For time trends see Tables:INF-108, INF-109, and INF-110

n.a. = not available

(1) The figures show estimates (or range of estimates) from National and/or Sub-National level samples.

(2) Self-reported test results are less reliable than biological test results.

DT: Diagnostic testing; SP: Seroprevalence study; SP-UAT: Seroprevalence study with unlinked anonymous testing; RDS: Respondent-driven sampling; SR: Data (partly) based on self reported test results.

(3) Having health problems is one selection criterion for admission to drug treatment in some countries or cities, due to long waiting lists or special programmes for infected IDUs, and this may result in upward bias of prevalence. Prevalence from treatment data should therefore be interpreted in combination with non-treatment data. On the other hand, data from Italy and Portugal include non-IDUs and may thus underestimate prevalence in IDUs.

(4) § IDUnk = IDU status not known, prevalence in IDUs is likely to be underestimated.

(5) ODD = Overdose Deaths; DEM = Drug Emergencies; DTC = Drug Treatment Centres; NSP = Needle Exchanges; LTS = Low-Threshold Services; PHL = Public Health Laboratories; STI = STI Clinics; ANT = Antenatal Clinics; OHC = Other Hospital or Clinics; PRI = Prisons; ARR = Arrests; GPS = General Practitioners; HTC = HIV Testing Centres; STR = Street; OTH = Other.

^^ A study from 2010 is included too (the 2011 is from Amsterdam and the other from Rotterdam)

*** In 2010, data from 2 studies (SP study in DTCs using serum as specimen and DT study in DTCs using serum and DBSs as specimen) were provided and in 2011 data only from one of those were submitted (DT study). However, the estimates from the two studies vary a lot, and so both estimates are provided here to allow for this variation

* Italy provided a national estimate for 2010 only, even though regional data for 2011 were provided for many regions, but not for all (i.e. Liguria and Lombardia). So regional data for 2010 and not for 2011 are presented here as well for comparability reasons

Sources:

See Table INF-108 .

For references see Table INF-0. Bibliographic References-Part A: References for prevalence data

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013